Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
oritinib (SH-1028)
i
Other names:
SH 1028, SH-1028
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Twitter
Trials
Company:
Nanjing Sanhome Pharma
Drug class:
EGFR inhibitor, Tyrosine kinase inhibitor
Related drugs:
‹
cetuximab (317)
osimertinib (240)
erlotinib (229)
afatinib (217)
gefitinib (183)
panitumumab (114)
lapatinib (105)
neratinib (102)
pyrotinib (64)
brigatinib (45)
icotinib (39)
aumolertinib (22)
amivantamab-vmjw (15)
BGB-283 (12)
furmonertinib (11)
lazertinib (9)
mobocertinib (7)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
ASLAN001 (6)
CL-387785 (5)
nimotuzumab (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
BLU-945 (4)
tomuzotuximab (4)
GB263T (4)
JIN-A02 (4)
TAS2940 (4)
EGF816 (4)
BBT-176 (3)
BLU-701 (3)
GC-1118A (3)
ASP8273 (3)
DZD9008 (3)
BCA101 (2)
BI-732 (2)
Bay846 (2)
MCLA-129 (2)
OBX02-011 (2)
olmutinib (2)
necitumumab (2)
QL1203 (2)
S95026 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
AFM24 (1)
APL-103 (1)
BLU-451 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
ORIC-114 (1)
befotertinib (1)
TAS3351 (1)
S-222611 (1)
HMPL-813 (1)
ASK120067 (1)
MET306 (1)
HLX07 (1)
KD019 (1)
AZD3759 (1)
PD 0173074 (9)
E 3810 (4)
AG-1296 (1)
X-82 (1)
cetuximab (317)
osimertinib (240)
erlotinib (229)
afatinib (217)
gefitinib (183)
panitumumab (114)
lapatinib (105)
neratinib (102)
pyrotinib (64)
brigatinib (45)
icotinib (39)
aumolertinib (22)
amivantamab-vmjw (15)
BGB-283 (12)
furmonertinib (11)
lazertinib (9)
mobocertinib (7)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
ASLAN001 (6)
CL-387785 (5)
nimotuzumab (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
BLU-945 (4)
tomuzotuximab (4)
GB263T (4)
JIN-A02 (4)
TAS2940 (4)
EGF816 (4)
BBT-176 (3)
BLU-701 (3)
GC-1118A (3)
ASP8273 (3)
DZD9008 (3)
BCA101 (2)
BI-732 (2)
Bay846 (2)
MCLA-129 (2)
OBX02-011 (2)
olmutinib (2)
necitumumab (2)
QL1203 (2)
S95026 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
AFM24 (1)
APL-103 (1)
BLU-451 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
ORIC-114 (1)
befotertinib (1)
TAS3351 (1)
S-222611 (1)
HMPL-813 (1)
ASK120067 (1)
MET306 (1)
HLX07 (1)
KD019 (1)
AZD3759 (1)
PD 0173074 (9)
E 3810 (4)
AG-1296 (1)
X-82 (1)
›
Associations
(1)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
SH-1028
Sensitive: C2 – Inclusion Criteria
SH-1028
Sensitive
:
C2
SH-1028
Sensitive: C2 – Inclusion Criteria
SH-1028
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login